Omeros seeks orphan-drug status for rare disease drug

04/22/2013 | Pharmaceutical Business Review Online

Omeros submitted an application to the FDA seeking orphan-drug designation for OMS721, an investigational drug for atypical hemolytic uremic syndrome. The drug, which targets the lectin pathway of the complement system, is formulated for self-administration through subcutaneous injection. The firm plans to apply for a similar designation in Europe and to initiate clinical studies in the summer.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA